Subscribe to our newsletter

SPHERES: Neuromyelitis Optica Spectrum Disorder (NMOSD) Registry

CorEvitas is now part of Thermo Fisher Scientific. Read More.

200 +

STUDY VISITS

190 +

PATIENTS

20 +

SITES

70 +

MDS

15 +

STATES

Participating Sites

CorEvitas has clinical sites across the U.S. and we are always interested in expanding the registry for qualified sites.

Outcome measures in the CorEvitas NMOSD Registry

Among the variables we collect, some of the key outcome measures to inform your research include:

Disease Characteristics

Primary Diagnosis
Year of onset and diagnosis of NMOSD
Details of neurological episodes (initial and subsequent relapses)
2015 IPND international consensus diagnostic criteria characteristics
Serology Status (AQP4, MOG)
EDSS (expanded disability status scale) Step Score
Montreal Cognitive Assessment (MoCA)
History of Infections
Comorbidity and Medical History

Patient Reported Outcomes

Modified Fatigue Impact Scale (MFIS)
PainDETECT Questionnaire (PD-Q)
EuroQol Visual Analogue Scale (EQ-VAS)
5-level EQ-5D version (EQ-5D-5L)
Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
Pain Severity Numeric Rating Scale
Patient Health Questionnaire-2 (PHQ-2)
Visual Function Questionnaire - Utility Index (VFQ-UI)

Contact the SPHERES Registry Team:

NMOSD@corevitas.com or (508) 408-5426

OUR PARTNERS

In Partnership with the Guthy Jackson Charitable Foundation

Our Publications

Other Registries

Question about a registry?